Prima BioMed Pre-Tax Profit Margin 2010-2021 | IMMP
Prima BioMed pre-tax profit margin from 2010 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
| Prima BioMed Pre-Tax Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Pre-Tax Income | Pre-Tax Margin |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Biomedical and Genetics | $0.254B | $0.003B |
| Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bristol Myers Squibb (BMY) | United States | $162.107B | 9.86 |
| Bio-Rad Laboratories (BIO.B) | United States | $15.121B | 32.79 |
| QIAGEN (QGEN) | Netherlands | $10.761B | 16.99 |
| Biohaven Pharmaceutical Holding (BHVN) | United States | $10.111B | 0.00 |
| Ginkgo Bioworks Holdings (DNA) | United States | $5.648B | 0.00 |
| Emergent Biosolutions (EBS) | United States | $1.770B | 7.57 |
| Arcus Biosciences (RCUS) | United States | $1.376B | 34.89 |
| Myovant Sciences (MYOV) | United Kingdom | $1.033B | 0.00 |
| Zymeworks (ZYME) | Canada | $0.397B | 0.00 |
| Gelesis Holdings (GLS) | United States | $0.345B | 0.00 |
| Ambrx Biopharma (AMAM) | United States | $0.157B | 0.00 |
| Enzo Biochem (ENZ) | United States | $0.110B | 22.60 |
| SQZ Biotechnologies (SQZ) | United States | $0.100B | 0.00 |
| ADC Therapeutics SA (ADCT) | Switzerland | $0.000B | 0.00 |
